Pharmaceutical: Germany Expected to be the Fastest Growing Heparin Market in Europe Expanding at a CAGR of 6.0% by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022” the Europe heparin market was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.

Browse the full Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/europe-heparin-market.html

The heparin market in Europe has been categorized into major national markets namely, the United Kingdom, Germany, Spain, Italy, France, and Rest of Europe. The European market is among the major contributors to the global heparin market owing to its developed economy and high prevalence of coagulation disorders. In the current scenario, according to the 2015 Ageing Report by the European Commission, the percentage of population aged above 65 years is expected to increase from 21% in 2013 to 32% in 2060. As aging is proportional to increasing incidences of VTE diseases such as deep vein thrombosis (DVT) and pulmonary embolism (PE) demand for heparin is expected to increase in coming years.

Germany accounts for the largest market share in the overall Europe heparin market accounting for around 274.8 million in 2013. Key attributes to the market growth in Germany encompasses burgeoning population of venous thromboembolism (VTE) patients owing to which the consumption of heparin has grown at a rapid pace over the past few years. Moreover, ban of Chinese APIs due to adulterated issue leading to over 100 deaths in the U.S., has drastically attracted new players in heparin processing and manufacturing business. For instance in 2013, German meat company Tönnies group acquired heparin API manufacturer Pharma Action which proposed to manufacture 30 metric tons of API in forthcoming years. For instance, Germany-based meat company Tönnies Group entered the heparin processing business by acquiring heparin API maker Pharma Action. Such developments are expected to augment heparin market in Germany.

Followed by Germany, France has major contribution to the heparin market in the Europe. Each year 370,000 deaths in France occur due to VTE. Moreover, Heparin consumption during and after surgical procedures such as knee replacement, hip surgeries, appendectomy and breast surgeries are relatively high compared to Italy, Spain and United Kingdom. It is estimated that every fourth person in France by 2020 would be aged above 60 years. Rapidly aging population and growing life expectancy would increase the risk of thrombosis among the geriatric population. According to the Thrombosis Research Institute, around 25,000 deaths occur annually in England due to hospital-contracted VTE. Based on the recommendations from the chief medical officer (CMO), the Department of Health in the U.K. published an operating framework for the NHS in England. This framework requires risk assessment to be done for thrombosis in a minimum of 90% of patients admitted to hospitals. All these factors are likely to support the growth in demand for heparin for prophylaxis and treatment of thrombosis during the forecast period.

Browse the full Press Release Report : http://www.transparencymarketresearch.com/pressrelease/geography-heparin-market.htm

Spain, Italy and Rest of the Europe markets although have low revenue contribution in European heparin market is expected to grow in forthcoming years. Spain's National Institute of Statistics (INE) predicts that the Spanish population would shrink by 5.6 million before 2064. Additionally, about 40% of the population would be aged over 65 years, which is an increase from 18.2% in 2013. The United Nations (UN) projects that Spain would be the world’s oldest country by 2050. This is a major factor attributed to an increased risk of thrombosis, which would further propel demand for heparin in the region. Such factors along with increasing investment in elderly care would propel the demand for heparin in Italy. As of 2014, there is only one drug licensed (Rivaroxaban; Xarelto) for the treatment of VTE in Italy. Advent of biosimilars would augment the growth of heparin market in Italy during the forecast period. Some of the key players profiled in this report include Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Leo Pharma A/S, Pfizer, Inc., Sanofi S.A., and Syntex S.A. are profiled in this report.

The Europe Heparin Market is segmented into the following categories:

Europe Heparin Market, by Product

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)